Antithrombotic treatment after left atrial appendage closure (n=146)
| Antithrombotic treatment | Discharge | 6 weeks p/LAAC | 3 months p/LAAC | 6 months p/LAAC | 1 year p/LAAC |
| AP monotherapy | 1 (0.6%) | 28 (19.2%) | 96 (65.7%) | 114 (78.1%) | 110 (75.3%) |
| DAPT | 43 (29.5%) | 85 (58.2%) | 25 (17.1%) | 6 (4.1%) | 1 (0.6%) |
| Warfarin | 3 (2.0%) | 0 | 0 | 1 (0.6%) | 0 |
| Warfarin+AP | 8 (5.5%) | 2 (1.4%) | 1 (0.6%) | 0 | 1 (0.6%) |
| DOAC | 42 (28.8%) | 19 (13.0%) | 8 (5.5%) | 5 (3.4%) | 6 (4.1%) |
| DOAC+AP | 49 (33.6%) | 10 (6.8%) | 2 (1.4%) | 2 (1.4%) | 3 (2.0%) |
| None | 0 | 1 (0.6%) | 4 (2.8%) | 6 (4.1%) | 6 (4.1%) |
| Died | 0 | 1 (0.6%) | 1 (0.6%) | 1 (0.6%) | 5 (3.4%) |
| Lost to follow- up | 0 | 0 | 9 (6.2%) | 11 (7.5%) | 14 (9.6%) |
AP, antiplatelet; DAPT, dual antiplatelet therapy; DOAC, direct oral anticoagulant; LAAC, left atrial appendage closure.